MedTrace Logo

Efficacy and Safety of Tadalafil in Hemodialysis Patients

NCT00334477 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2006-06-07

No results posted yet for this study

Summary

The purpose of this study is to check the safety and efficacy of a pde5 inhibitor, tadalafil, is a special group of patients: Renal chronic patients in hemodialysis treatment.

Conditions

Interventions

DRUG

tadalafil

Sponsors & Collaborators

  • University of Pernambuco

    lead OTHER

Principal Investigators

  • bruno sp carvalho, md · University of Pernambuco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00334477 on ClinicalTrials.gov